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ABSTRACT
Vascular endothelial growth factor (VEGF) pathway targeting agents have been 
combined with other anticancer drugs, leading to improved efficacy in carcinoma of 
the cervix, stomach, lung, colon and rectum, ovary, and breast. Vessel normalization 
induced by VEGF pathway targeting agents influences tumor drug uptake. Following 
bevacizumab treatment, preclinical and clinical studies have shown a decrease in 
tumor delivery of radiolabeled antibodies and two chemotherapeutic drugs. The 
decrease in vessel pore size during vessel normalization might explain the decrease 
in tumor drug uptake. Moreover, the addition of bevacizumab to cetuximab, or 
panitumumab in colorectal cancer patients or to trastuzumab in breast cancer patients, 
did not improve efficacy. However, combining bevacizumab with chemotherapy did 
increase efficacy in some cancer types. Novel biomarkers to select patients who may 
benefit from combination therapies, such as the effect of an angiogenesis inhibitor 
on tumor perfusion, requires innovative trial designs and large clinical trials. Small 
imaging studies with radiolabeled drugs could be used in the interphase to gain 
further insight into the interplay between VEGF targeted therapy, vessel normalization 
and tumor drug delivery.
INTRODUCTION
Angiogenesis is a hallmark of cancer that enables 
tumor growth [1]. Vascular endothelial growth factor 
A (VEGF-A) is a key player in the process of tumor 
angiogenesis, and the VEGF pathway has therefore been 
an important focus for anti-cancer drug development [2, 
3]. Although angiogenesis is recognized to enable tumor 
growth, some tumors are capable of growing independent 
of angiogenesis by vessel co-option [4].
Antiangiogenic treatment blocks the formation 
of new blood vessels. The initially high hopes of VEGF 
pathway targeting agents as panacea for treatment of 
solid tumors have been replaced by a more realistic 
definition of their role. Single agent activity has been 
shown in renal cell carcinoma, hepatocellular carcinoma, 
pancreatic neuroendocrine tumors, soft tissue sarcomas 
and in colorectal cancer. VEGF pathway targeting drugs 
have been added to other anticancer drugs to improve 
their efficacy. This approach has only been successful in 
carcinoma of the cervix, stomach, lung, colon, rectum, 
ovary, and breast [5-7]. Improved understanding of the 
underlying mechanisms could support rational drug 
combinations.
Preclinical and clinical studies have indicated 
that anti-VEGF therapy induces changes in function 
and architecture of existing blood vessels, described as 
vessel normalization [8]. Major characteristics of vessel 
normalization are reduced number and size of immature 
vessels, increased vessel pericyte coverage and reduced 
interstitial fluid pressure (IFP) [8, 9].
Another consideration is that changes in tumor 
vasculature caused by anti-VEGF therapy could also affect 
tumor uptake of other drugs. If preclinical data could be 
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used to predict the behavior of combination therapy, this 
would be of great benefit in the clinic. At present, however, 
translation of preclinical antiangiogenesis data to the clinic 
remains challenging. We reviewed the literature on the 
interplay between VEGF pathway targeting agents, vessel 
normalization and tumor drug delivery in the preclinical 
and clinical setting.
Vessel normalization and VEGF-targeted agents
The vascular organization and structure of tumors 
differs from normal tissue [10]. Tumor vasculature is more 
tortuous and chaotic, with inadequate pericyte coverage, 
increased breaches between endothelial cells and 
alternating thick and thin basement membranes. This leads 
to increased vessel permeability and high IFP causing 
hypoxia [8, 9] Preclinical studies have shown that anti-
VEGF therapy can initiate vessel normalization. Vessel 
normalization is measured in the preclinical and clinical 
setting by decreased vessel diameter, blood volume, mean 
vessel density (MVD), macromolecular permeability, IFP 
and edema. Vessel normalization leads to an increase in 
partial oxygen pressure and perivascular cell coverage in 
the tumor [8, 9, 11-15]. In this review, we defined vessel 
normalization as pruning and remodeling of abnormal 
tumor vessels, leading to vessels resembling normal tissue 
vasculature in terms of structure and function [8, 9].
Translating preclinical insights about vessel 
normalization to the clinic has been challenging. This is 
due in part to the differences between tumor-bearing mice 
and human patients. Murine models with subcutaneous, 
fast-growing human tumors are generally used [16, 17]. In 
patients, primary tumor lesions can be located anywhere 
in the body and usually are slow-growing, with doubling 
times of months to years compared to weeks in murine 
models. Even with metastatic disease, clinical progression 
is generally much slower than in murine models. In 
addition, preclinical models often comprise a single, 
subcutaneous human tumor with murine vasculature. 
These tumors are often treated for weeks, at most. In 
patients, tumor and vasculature are of human origin, and 
long-term treatment is required for optimal antitumor 
effect. Furthermore, normal vasculature in patients will be 
aged, as for most cancers incidence rates increase with 
age [18]. To improve translation to the clinic, preclinical 
studies should ideally be representative for the stage of 
disease treated in the clinic, consist of tumor cells with 
a compatible immunocompetent microenvironment and 
examine combination therapies at appropriate dosages 
analogous to the clinic [19-21].
At the moment several VEGF pathway targeting 
agents are available. Registered drugs include small 
molecule tyrosine kinase inhibitors (TKI) targeting the 
VEGF receptors (VEGFR), and antibodies targeting 
VEGF and VEGFR2.
VEGFR TKIs
A recent meta-analysis evaluated the efficacy and 
safety of combining VEGFR TKIs with chemotherapy in 
patients with solid tumors [22]. Data from 24 randomized 
controlled trials with a total of 8,961 patients was 
analyzed, with 879 patients participating in axitinib 
trials, 3,761 in sorafenib trials, 1,970 in sunitinib trials 
and 2,351 in vandetanib trials. The addition of VEGFR 
TKIs to chemotherapy increased side effects. There was 
an increase in any adverse events (relative risk 1.34, 95% 
confidence interval (CI) 1.20 - 1.50, P < .001) and fatal 
adverse events (relative risk 1.49, 95% Cl 1.16 - 1.90, P 
= .002) [22].
Results from numerous phase 3 trials combining 
VEGFR TKIs with chemotherapy showed only marginal 
to no increased antitumor efficacy (Table 1). When 
combined with chemotherapy in metastatic colorectal 
cancer (mCRC), neither vatalanib (first- and second-line 
treatment) nor sunitinib (first-line treatment ) increased 
progression-free survival (PFS) or overall survival (OS) 
[23-25]. In the randomized phase 3 HORIZON II trial, 
combination of cediranib with chemotherapy led to a 
clinically irrelevant increase of 0.3 months in PFS (HR 
0.84, P = .012), and had no effect on OS as first-line 
therapy in mCRC patients [26]. In addition, in metastatic 
breast cancer sunitinib had no effect on PFS or OS when 
combined with chemotherapy as first- and second-line 
therapy [27, 28]. In non-small cell lung cancer (NSCLC), 
addition of sorafenib to chemotherapy in the first-line 
had no effect on OS [29, 30]. Combining vandetanib 
with chemotherapy as second line NSCLC therapy in 
the randomized phase 3 ZODIAC trial led to an increase 
in PFS of 0.8 months (HR 0.79, P < .0001) [31]. The 
randomized phase 3 ZEAL trial trial showed a positive 
trend in PFS, but no significant increase, when vandetanib 
was combined with chemotherapy in second-line treatment 
[32]. In the LUME-Lung 1 randomized phase 3 trial, the 
addition of nintedanib to chemotherapy in the second line 
increased PFS with 0.7 months (HR 0.79, P = .002), but 
did not increase OS. A beneficial effect of 2.3 months (HR 
0.83, P = .036)on OS was only seen in the subgroup of 
patients with a histological defined adenocarcinoma [33].
Recently, the randomized phase 2 CIRCCa trial in 
metastatic and recurrent cervical cancer patients showed 
that the addition of cediranib to chemotherapy improved 
PFS with 1.4 months (HR 0.58, P = .032) compared to 
placebo. However, the addition of cediranib did not 
increase OS in these patients [34].
In recurrent glioblastoma multiforme (GBM) 
patients, combining cediranib with chemotherapy in the 
randomized phase 3 REGAL trial did not increase PFS 
and had no effect on OS [35]. A small prospective study 
measured tumor blood perfusion changes with magnetic 
resonance imaging (MRI) during cediranib treatment 
in 30 recurrent GBM patients to evaluate the vascular 
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normalizing effects of cediranib [36]. Tumor perfusion 
increased in 7, decreased in 11 and remained stable in 
12 patients. OS prolonged to 348 days in patients with 
increased perfusion, compared to 169 or 213 days in 
patients with respectively stable or decreased perfusion 
(P = .019). In another prospective study, patients with 
newly diagnosed GBM received 30 mg/day cediranib 
with chemoradiation (n = 40) or chemoradiation alone 
(n = 14) [37]. Cediranib increased perfusion in 20 (50%) 
patients, decreased perfusion in 10 (25%) patients, and 
in 10 (25%) patients perfusion remained stable. These 
changes occurred at day 1 and became stable around day 
Table 1: Results from phase III trials combining antiangiogenic therapy with chemotherapy or monoclonal antibodies
Abbreviations: VEGFR TKI= vascular endothelial growth factor receptor tyrosine kinase inhibitor, B=bevacizumab, 
CH=chemotherapy, NSLC= non-small cell lung cancer, PFS= progression free survival, OS= overall survival, NS= no 
significant difference, mo=months, Ref=reference.
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8. However, in one out of the 14 (7%) control patients, 
perfusion increased with chemoradiation alone. In the 
combination group, increased perfusion was associated 
with a median OS of 26.3 months compared to 17.0 months 
for patients without increased perfusion (P = .028). Based 
on MRI analyses, these two studies show that cediranib 
increased perfusion in a subgroup of GBM patients, 
which correlated with increased survival. These results 
suggested that increased tumor perfusion by cediranib 
induced vessel normalization might lead to increased 
tumor drug uptake and improved outcome in these patients 
[36, 37]. In addition to these studies, preclinical studies 
have shown that antiangiogenic therapy could potentiate 
radiotherapy by improving tumor oxygenation [38]. In 
randomized studies this did not translate to OS benefit. 
In newly diagnosed glioblastoma patients 2 randomized 
phase 3 trials, AVAglio and RTOG0825, studied the 
effect of the addition of bevacizumab to chemotherapy 
and radiotherapy. Both trials showed that the addition of 
bevacizumab did improve PFS (4.2 months in AVAglio 
(HR 0.64, P < .001) and 3.4 months in RTOG0825 (HR 
0.79, P =.007), but had no effect on OS compared to 
placebo [39, 40].
Blood flow and perfusion are closely related terms. 
Strictly speaking blood flow is defined as blood volume 
per time, whereas perfusion stands for blood volume per 
time per amount of tissue. This means that blood flow can 
be high, while perfusion e.g. as expressed per 100 g of 
tissue is low. Accurate measurement of tumor perfusion is 
of interest in determining effects of antiangiogenic therapy 
or evaluating drug delivery. Interesting imaging modalities 
to measure tumor perfusion in a noninvasive matter are 
PET and dynamic contrast-enhanced (DCE) CT or MRI. In 
DCE imaging a contrast agent is given and images made 
before, during and after injection are necessary to calculate 
contrast concentrations in the area of interest. In case of 
PET imaging, the tracer is injected and scans are made to 
directly measure tracer uptake. During DCE-MRI or CT 
imaging, contrast agents are used to measure perfusion. 
These contrast agents are not freely diffusible, thus uptake 
does not solely represent tumor perfusion. However 
they also provide insight in vasculature permeability. 
H215O-PET is a freely diffusible tracer, thereby directly 
illustrating tumor perfusion. Furthermore, there is a linear 
relation between H215O or contrast agent concentration 
and signal intensity as measured by PET or DCE-CT, 
which enables direct quantification. There is no linear 
relationship between contrast agent concentration and 
signal intensity as measured by DCE-MRI, complicating 
quantification of tumor perfusion [41 - 43]. 
Figure 1: Hypothetical trial to evaluate tumor perfusion as a predictive biomarker for survival in GBM patients. To 
identify the biomarker-positive cohort, initially all patients are randomized to chemoradiotherapy with or without cediranib. In a second 
phase, only patients with increased perfusion after 8 days on treatment are randomized to continue chemoradiotherapy either with or 
without cediranib.
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To provide insight into the implications of 
patient selection based on perfusion, we designed a 
hypothetical trial using an enrichment design for primary 
GBM patients treated with cediranib and/or standard 
chemoradiotherapy (Figure 1) [44, 45]. In such a design, 
the biomarker is evaluated in all randomized patients, 
but only patients who are defined as biomarker-positive, 
i.e. patients with increased tumor perfusion after 8 
days on initial randomized treatment, are eligible for a 
second randomization [45]. To identify the biomarker-
positive cohort, initially all patients are randomized 
to chemoradiotherapy with or without cediranib. In a 
second phase, only patients with increased perfusion 
after 8 days on treatment are randomized to continue 
chemoradiotherapy either with or without cediranib. The 
OS would be compared between randomized arms, to 
evaluate whether addition of cediranib provides benefit in 
patients who achieved increased perfusion, irrespective of 
the initial treatment that led to this increase. Patients with 
decreased or stable perfusion would be taken off study and 
complete standard chemoradiotherapy. The second study 
phase requires 310 patients, to achieve 80% power at a 
two-sided α of 5%, assuming an OS improvement of 35% 
(HR = 0.65). This implies that 1,602 patients should have 
been enrolled upfront in the first randomization, with 460 
and 1142 patients initially randomized to treatment with or 
without cediranib (respectively corresponding to 230 and 
80 patients with increased perfusion at 8 days under initial 
treatment). This is a very large number of GBM patients; 
the landmark paper demonstrating the additive effect of 
chemotherapy to first line radiotherapy in GBM required 
573 patients, accrued during 20 months in 85 centers in 20 
countries [44].
Bevacizumab
So far, combining another antibody with 
bevacizumab plus chemotherapy have shown detrimental 
to modestly beneficial effects (Table 1). For mCRC, 
combining bevacizumab, the anti-EGFR antibody 
cetuximab and chemotherapy in the phase 3 CAIRO2 
trial did not improve OS compared to bevacizumab with 
chemotherapy alone. In fact, the addition of cetuximab 
decreased PFS by 1.2 months (HR 1.22, P = .01) [46]. 
Furthermore, patients receiving cetuximab, bevacizumab 
and chemotherapy experienced more cetuximab-related 
side effects. Similar results were obtained in the phase 3 
PACCE trial in mCRC patients receiving bevacizumab 
with chemotherapy or bevacizumab, chemotherapy and the 
anti-EGFR antibody panitumumab. In the panitumumab 
group, PFS decreased by 1.4 months (HR 1.27) and no 
effect was observed on OS [47].
In the phase 3 AVEREL trial in metastatic HER2 
positive breast cancer patients, chemotherapy with 
anti-HER2 antibody trastuzumab or chemotherapy, 
trastuzumab and bevacizumab was administered [48]. 
Addition of bevacizumab marginally affected PFS (13.7 
months without versus 16.5 months with bevacizumab; 
HR 0.82, P = .07). Another randomized phase 3 trial in 
metastatic HER2 positive breast cancer patients also 
showed that addition of bevacizumab to trastuzumab and 
chemotherapy did not increase PFS (11.1 months without 
versus 12.2 months with bevacizumab; HR 0.65, P = .10) 
[49]. Furthermore, in the randomized phase 3 BETH trial 
in early HER2 positive breast cancer patients the addition 
of bevacizumab to trastuzumab and chemotherapy had no 
effect on invasive disease free survival and OS at a median 
follow up of 38 months [50].
It has been suggested that vessel normalization 
could improve tumor drug uptake. In three small rectal 
cancer studies, comprising 5, 6 and 32 patients, vessel 
normalization induced by 5-10 mg/kg bevacizumab 
was investigated with biopsies, IFP measurements and 
functional computed tomography (CT) scans. At 12 days 
after bevacizumab administration, IFP decreased and the 
fraction of vessels covered with pericytes increased, while 
the permeability-surface area product remained stable. 
These findings indicate that bevacizumab induced vessel 
normalization in these patients [51-53]. However, this 
does not demonstrate a direct relationship between vessel 
normalization and improved tumor drug uptake. Imaging 
with radiolabeled drugs potentially provides a tool to 
quantify tumor drug uptake. Both preclinical and clinical 
studies have evaluated the effects of antiangiogenic 
therapy on tumor drug uptake. At the University Medical 
Center Groningen, we have developed 89Zr-labeled 
bevacizumab and 89Zr-trastuzumab as tracers for positron 
emission tomographic (PET) scanning to visualize and 
quantify bevacizumab and trastuzumab biodistribution 
for preclinical and clinical purposes [54-59]. These tracers 
can provide insight into how bevacizumab affects uptake 
of other antibodies. Despite limitations of animal models, 
these human grade tracers allow translation of preclinical 
findings to the clinic. In two xenograft models of human 
HER2-positive ovarian cancer (SKOV-3) and esophageal 
cancer (OE19) we used PET imaging to evaluate tumor 
uptake of radiolabeled trastuzumab (SKOV-3 and OE19), 
IgG (in SKOV-3) and bevacizumab (SKOV-3), before and 
after bevacizumab treatment [60]. On day 6, after three 
doses of 5 mg/kg bevacizumab, tumor uptake decreased 
by 41% and 39% for trastuzumab in SKOV-3 and OE19, 
respectively. For radiolabeled IgG and bevacizumab, 
tumor uptake decreased by 28% and 44% respectively 
after bevacizumab treatment. These results indicate that 
bevacizumab treatment affected antibody tumor uptake 
negatively. Bevacizumab therapy reduced microvessel 
density (MVD) in tumors and increased vessel pericyte 
coverage, indicating both anti-vascular and vessel 
normalizing effects of bevacizumab.
Two other preclinical studies reported similar 
results [61,62]. One 10 mg/kg dose of cross-reactive anti-
VEGF antibody B20-4.1 decreased tumor trastuzumab 
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uptake by 50% after 2 days in a xenograft HER2-positive 
breast cancer model (KPL-4) [61]. Moreover, 10 mg/kg 
bevacizumab decreased tumor cetuximab uptake by 40% 
after 4 days in EGFR-positive breast cancer xenograft 
models (SUM149 and SKBR3) [62].
Importantly, these findings are supported in 
the clinical setting. A study in patients with renal cell 
carcinoma (n = 11) showed a 47% decrease of 89Zr-
bevacizumab tumor uptake 2 weeks after one therapeutic 
infusion of 10 mg/kg bevacizumab [63]. Thus, vessel 
normalization induced by bevacizumab seems to impair 
tumor delivery of antibodies. 
In addition, two clinical imaging studies suggest 
bevacizumab also affects tumor drug delivery of 
chemotherapeutic drugs. In NSCLC patients (n = 10), a 
single dose of 15 mg/kg bevacizumab reduced 11C labeled-
docetaxel tumor delivery by 22% after 5 hours and by 
34% after 4 days [64]. Moreover, tumor drug delivery 
of 18F-5-fluorouracil decreased by 20% at 24 hours after 
a single administration of 7.5 mg/kg bevacizumab in 
mCRC patients (n = 5) [65]. Phase 3 trials combining 
bevacizumab with chemotherapy show varying results. 
Bevacizumab combined with chemotherapy in colorectal, 
ovarian, cervical and HER2-negative breast cancer has 
shown an increase in PFS [66 - 70].
A small imaging study evaluated the effect of 
bevacizumab on tumor perfusion and survival in 36 
NSCLC patients [71]. Patients received a dose of 15mg/
kg bevacizumab as induction therapy, which after 14 days 
was followed by the combination of carboplatin, nab-
paclitaxel and bevacizumab for a maximum of 6 cycles 
of 21 days. Blood flow, blood volume and permeability 
surface, measured by CT, all decreased after induction 
and during combination therapy. In addition, mean transit 
time (MTT), a measurement for perfusion, showed a 
slight increase during combination therapy. This reflects a 
decrease in perfusion and was suggested to be associated 
with shorter survival in these patients (P = .05). Together 
with the cediranib imaging studies in GBM patients, these 
results suggest that perfusion could be a potential read-
out for vessel normalization and a possible predictive 
biomarker for survival [36, 37. 71].
VEGFR2 antibodies
Intravital imaging showed that DC101, an antibody 
against mouse VEGFR2, induced vessel normalization in 
an orthotopic mammary tumor model [72]. This particular 
study is a key paper as it provided insight into the effect 
of vessel normalization on pore size of tumor vasculature. 
The nanoparticles used were quantum dots coated 
with polymeric imidazole ligand (PIL) (ø = 12 nm) or 
polyethylene glycol (PEG) (ø = 60 and 120 nm) [73]. Pore 
size was determined by modeling nanoparticle penetration 
rate, given as transvascular flux per unit vascular surface 
area. Vessel normalization by DC101 coincided with a 
decrease in pore size of tumor vasculature, resulting in 
an increase of the penetration rate of small nanoparticles 
(12 nm) but no difference in penetration rate for 60 and 
120 nm size nanoparticles. This means that the effect of 
DC101 on pore size was mainly based on the difference 
in the transvascular flux of 12 nm particles in tumors with 
and without DC101 treatment. Moreover, in the E0771 
xenograft model treated with DC101, for example, a large 
spread in transvascular flux of 12 nm nanoparticles was 
already present in this group (from 0.05 - 0.3 µm s-1). 
Such a substantial variation leads to a large uncertainty in 
model outcomes on pore size, which was not discussed by 
the authors. Since antibodies are approximately 12 nm in 
size, similar to the small nanoparticles, it was suggested 
that DC101-induced vessel normalization may also 
improve tumor drug delivery of antibodies [74]. However, 
although their size is similar, there are substantial 
chemical differences between nanoparticles used in this 
study and antibodies, which may affect penetration rate 
[72, 73]. Firstly, nanoparticles are spherically shaped, 
whereas antibodies are Y-shaped [75, 76]. Secondly, the 
mass (density) of the nanoparticles and antibodies may 
be different. Thirdly, the chemistry of the outer shell of 
the nanoparticles used in this study is different than the 
chemistry of antibodies [72]. The PIL-coated 12 nm size 
nanoparticles have mainly methoxy (R-O-CH3) functional 
end groups in the outer shell, and the PEG-coated 60 and 
125 nm particles have hydroxyl (R-OH) functional end 
groups. On the other hand, antibodies, which can be seen 
as a combination of four biopolymers, mainly have R-NH2 
and R-COOH end groups [75, 76]. These differences can 
make it difficult to translate results from these specific 
nanoparticles to “nanomedicines” such as antibodies. 
This important study also investigated whether 
DC101-induced vessel normalization could improve 
efficacy of small chemotherapeutics [72]. Mice were 
treated with DC101, placebo, DC101 or placebo plus 
abraxane (albumin-bound paclitaxel, ø = 10 nm) and 
DC101 or placebo plus doxil (liposome-encapsulated 
doxorubicin, ø = 100 nm). Tumor doubling times were 
used as read-out for efficacy. Both DC101 alone and 
DC101 plus doxil had no effect on tumor doubling times 
compared to placebo or doxil plus placebo. However, 
DC101 plus abraxane did increase tumor doubling times 
compared to placebo plus abraxane. From these data it was 
concluded that the vessel-normalizing effects of DC101 
increased tumor penetration of abraxane. The results of 
control experiments in this article showed a large range 
in tumor doubling times in the placebo plus doxil group, 
which might have influenced the results for this group. 
In the clinic, VEGFR2 antibody ramucirumab, which 
is administered at much lower doses than in the mouse 
model, has shown very modest or no effect in 5 phase 3 
clinical trials (Table 1). Ramucirumab monotherapy (8 
mg/kg every 2 weeks) increased PFS by 0.8 months (HR: 
0.48, P < .0001) and prolonged OS by 1.4 months (HR: 
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0.77, P = .047) in gastric cancer and esophageal junction 
adenocarcinoma patients in the second line [77]. Adding 
ramucirumab (8 mg/kg every 2 weeks) to paclitaxel 
increased PFS from 2.9 months to 4.4 months (HR 0.63, 
P < .0001) and prolonged OS by 2.3 months from 7.4 
to 9.6 months (HR 0.80, P = .017) in advanced gastric 
and esophageal junction adenocarcinoma patients [78]. 
In addition, in NSCLC patients, 10 mg/kg ramucirumab 
every 3 weeks combined with docetaxel increased PFS by 
1.5 months (HR 0.76, P < .0001) and prolonged OS by 1.4 
months (HR 0.86, P = .023) as second-line therapy [79]. 
In mCRC, FOLFIRI combined with 8 mg/kg ramucirumab 
prolonged OS compared to FOLFIRI with placebo with 
1.6 months from 11.7 to 13.3 months (HR 0.85, P = 
.02) in the second line [80]. However, in breast cancer 
patients, 10 mg/kg ramucirumab every 3 weeks combined 
with docetaxel did not affect PFS or OS [81]. The FDA 
recently approved ramucirumab for advanced gastric and 
esophageal junction adenocarcinoma, metastatic NSCLC 
and mCRC patients.
DISCUSSION
To date, preclinical studies have shown that 
antiangiogenic therapy can induce vessel normalization. 
Clinical studies have illustrated that this is not just 
a preclinical phenomenon; it also occurs in patients. 
Although some studies have suggested that vessel 
normalization can improve drug delivery of chemotherapy 
and enhance efficacy of combination therapies, there 
is no direct evidence for better tumor drug uptake. On 
the contrary, both preclinical and clinical studies with 
radioactive labeled drugs have shown decreased tumor 
delivery of antibodies as well as chemotherapeutic agents. 
In the case of chemotherapy, this did not inevitably result 
in the absence of an additional effect of combination 
therapy, although it may explain the disappointing 
results and lack of synergism. In addition to vessel 
normalization, other mechanisms have been proposed to 
explain how antiangiogenic agents can improve efficacy 
of chemotherapy. Certain chemotherapeutic agents can 
have a local antiangiogenic effect by affecting endothelial 
cells. This can result in an increased mobilization of 
circulating endothelial progenitor cells, again promoting 
tumor angiogenesis. The addition of an antiangiogenic 
agent can thus counteract this response, thereby improving 
efficacy of chemotherapy. Furthermore, in response to 
chemotherapy VEGF and VEGF-receptor expression by 
tumor cells can increase. The addition of an antiangiogenic 
agent can subsequently enhance the anti-proliferative 
action of chemotherapy. Another mechanism proposed 
is that antiangiogenic agents can inhibit tumor cell 
repopulation in between chemotherapy cycles, thereby 
increasing efficacy [82-86].
In the case of antibodies, results from clinical trials 
in colorectal and breast cancer patients are in line with 
reduced antibody uptake after antiangiogenic therapy. A 
possible explanation for decreased uptake could be the 
change in vessel pore size during vessel normalization. 
This might influence tumor drug uptake, depending on the 
size, shape and chemical structure of the drug. New data 
from a different angle are in line with this interpretation. 
Wong et al. performed a study in NSCLC and pancreatic 
ductal adenocarcinoma tumor models with low-dose 
cilengitide, an antiangiogenic agent selectively inhibiting 
α
ν
 integrins, and verapamil [87]. The combination therapy 
led to an increase in blood flow and perfusion, MVD and 
vascular permeability in these tumors. 
Moreover, addition of gemcitabine (75 mg/
kg) or cisplatin (6 mg/kg) to the combination therapy 
reduced tumor growth and progression compared to 
placebo, gemcitabine or cisplatin treatment alone. High-
performance liquid chromatography-mass spectrometry 
showed that cilengitide combined with verapamil 
increased intratumoral drug delivery of gemcitabine. 
Overall these findings indicate that tumor angiogenesis 
or even vascular promotion therapy could improve drug 
delivery. 
Most research concerning vessel normalization 
has been performed on primary tumors. Preclinical and 
clinical studies have shown that vessel normalization is 
a delicate process, occurring during a certain timeframe 
and dependent on the dose of the antiangiogenic drug [9]. 
However, it remains unclear how vessel normalization 
will occur in the metastasized setting. In normal healthy 
tissue, tissue-specific vessel functions illustrate vessel 
heterogeneity for different organs [88]. This also applies to 
the tumor vasculature, and indeed, different types of tumor 
blood vessels have been identified [89, 90]. In NSCLC 
patients, for instance, the primary tumor and matched 
brain metastases differed in MVD, vessel maturity and 
VEGF expression [91]. 
Finally, regarding vessel normalization there is a 
need for a biomarker to evaluate this process in different 
tumor types and stages. Tumor perfusion is a potential 
biomarker to select patients who may benefit from 
combinations of antiangiogenic and other drugs. However, 
assessing the role of tumor perfusion requires innovative 
study designs and extensive clinical trials. A possible 
tool to eventually improve drug delivery to individual 
tumors, and thereby optimize outcomes of combination 
therapies, could be in vivo imaging of labeled drugs. This 
might clarify the interplay between vessel normalization 
and tumor drug delivery. Small clinical trials could be 
performed to visualize the effects of antiangiogenic drugs 
on the distribution of other labeled drugs, to provide serial 
information on whole body drug distribution, and to guide 
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